Landscape of emerging T cell therapies in cancer

Most of the companies founded in the last five years to develop engineered T cell cancer therapies are going beyond the charted course of hematological indications and autologous delivery, but the preference for sticking with CARs is only getting stronger as companies take on other forms of risk.

With six autologous CAR T therapies on the market for hematological cancers — one having reached blockbuster status — engineered T cell cancer therapies continue to attract investment. At least 55 such companies founded since 2018 have raised more than $9.7 billion in capital, eight of which have raised $3.3 billion in the public market...